BioSpace News Archive

HeartFlow, Inc., a leader in revolutionizing precision heartcare, announced new data which indicate that the information provided by the HeartFlow FFRct Analysis was a superior predictor of 10-year outcomes compared to the severity of a coronary stenosis shown on a coronary computed tomography angiogram.

Novel multi-protein blood test data on more than 1,500 patients presented at 2021 American College of Cardiology Scientific Sessions

CEL-SCI Corporation Reports Second Quarter Fiscal 2021 Financial Results

Poster to highlight positive safety and efficacy signals demonstrated in ongoing proof-of-concept large animal study evaluating i-MSC stem cell therapy in acute lung injury

Edwards Lifesciences announced that clinical results from the company’s transcatheter mitral and tricuspid programs were presented as part of the late-breaking clinical trials at EuroPCR 2021, demonstrating positive outcomes for patients impacted by mitral or tricuspid heart valve disease.

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced receipt of regulatory feedback from the U.S. Food and Drug Administration (FDA) regarding its potency assays for lifileucel.

STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2021 fourth quarter ended March 31, 2021.

Transcat, Inc., a leading provider of accredited calibration, repair, inspection and laboratory instrument services and value-added distributor of professional grade handheld test, measurement and control instrumentation, reported financial results for its fourth quarter and fiscal year ended March 27, 2021.

Edwards Lifesciences announced the results of a real-world study comparing outcomes for patients with bicuspid aortic stenosis who were treated with SAPIEN 3 and SAPIEN 3 Ultra Transcatheter Aortic Valve Replacement and at low risk of death from surgery.

Medpace Holdings, Inc. announced that it will present at the following investor conference